Peptides for Growth Hormone

2 research peptides are currently studied for growth hormone. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Ghrelin is a 28-amino acid peptide produced predominantly in the stomach, recognized as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a). As the only known circulating orexigenic hormone, ghrelin plays a crucial role in stimulating appetite and regulating energy homeostasis. Research indicates that ghrelin not only promotes the release of growth hormone but also enhances appetite and facilitates fat storage, thereby influencing metabolic processes. A critical aspect of ghrelin's biological activity is its requirement for n-octanoylation at the Ser3 position, a post-translational modification essential for receptor binding and activation. Clinical applications have emerged, particularly with pharmaceutical analogs such as anamorelin, which has been developed for addressing cancer-related cachexia. Studies suggest that ghrelin's multifaceted effects on growth hormone release and appetite regulation make it a significant focus in metabolic research, although the complexity of its physiological roles warrants further investigation into its long-term safety and efficacy in various populations.

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to enhance the pharmacokinetic profile of GHRH. This compound incorporates a unique lysine-linked maleimidopropionic acid moiety that allows for covalent binding to circulating albumin, thereby extending its half-life from mere minutes (as seen with native GHRH) to approximately eight days. This extended half-life facilitates a dosing regimen of once or twice weekly, allowing for sustained elevation of growth hormone levels. Notably, while the DAC version of CJC-1295 provides a continuous release of growth hormone, it contrasts with the non-DAC variant, which maintains a pulsatile release pattern typical of endogenous physiology. This characteristic of CJC-1295 with DAC presents both advantages in terms of convenience for dosing and potential drawbacks related to the non-physiological GH release pattern. Preliminary data from Phase I and II trials indicate its potential utility in various clinical contexts; however, further research is necessary to fully elucidate its safety profile and long-term effects on growth hormone dynamics.